Sutro Biopharma - Asset Resilience Ratio
Sutro Biopharma (STRO) has an Asset Resilience Ratio of 56.57% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See STRO working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Sutro Biopharma's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Sutro Biopharma assets under control.
Liquid Assets Composition Over Time
This chart breaks down Sutro Biopharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Sutro Biopharma (STRO) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $110.01 Million | 56.57% |
| Total Liquid Assets | $110.01 Million | 56.57% |
Asset Resilience Insights
- Very High Liquidity: Sutro Biopharma maintains exceptional liquid asset reserves at 56.57% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Sutro Biopharma Industry Peers by Asset Resilience Ratio
Compare Sutro Biopharma's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Sutro Biopharma (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Sutro Biopharma.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 47.92% | $83.30 Million | $173.83 Million | +15.23pp |
| 2024-12-31 | 32.69% | $126.59 Million | $387.21 Million | -32.39pp |
| 2023-12-31 | 65.08% | $306.35 Million | $470.74 Million | -5.47pp |
| 2022-12-31 | 70.55% | $287.11 Million | $406.94 Million | +21.48pp |
| 2021-12-31 | 49.07% | $167.52 Million | $341.41 Million | +7.97pp |
| 2020-12-31 | 41.10% | $161.99 Million | $394.11 Million | -31.10pp |
| 2019-12-31 | 72.20% | $112.90 Million | $156.37 Million | +36.71pp |
| 2018-12-31 | 35.49% | $79.19 Million | $223.14 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $40.77 Million | -- |
| 2016-12-31 | 51.86% | $35.93 Million | $69.28 Million | -- |
About Sutro Biopharma
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid… Read more